Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix and Decode Collaborate on Gene Tests for Common Diseases

NEW YORK, July 24 - Affymetrix and DeCode Genetics have signed an agreement to develop DNA-based tests for patient response to common disease treatments using Affymetrix GeneChip technology, the companies said Tuesday.

The companies willl conduct gene expression analysis on clinical trial populations to discover the genetic correlates for responses to drugs in diseases including high-cholesterol, depression, asthma, hypertension, breast cancer, schizophrenia and migraine. DeCode’s wholly-owned  pharmacogenomics subsidiary EnCode will conduct the clinical work in this collaboration. 

"By combining DeCode’s population resources for pharmacogenomics with Affymetrix' high-density GeneChip platform, we hope to expand the clinical use of gene expression profiles to predict drug response," Stephen Fodor, Affymetrix’ CEO, said in a statement. “We believe these studies will generate valuable new indicators of disease, thereby contributing to the development of more effective therapies."

Affymetrix and Decode, through Encode, will share any revenues from DNA-based tests the parties develop under the collaboration. The parties did not disclose further terms of the agreement.  
The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.